• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapy and medication do not work for many patients suffering from depression. A customized treatment could be the solution.

Cue is a digital intervention platform that transforms passively acquired smartphone sensor data into personalized micro-interventions to improve mental health. We looked at the best-fitting personal ML models to each person using Shapley values to discover their feature predictors. The results revealed distinct characteristics that changed mood in a predictable manner over time.

Predictors of Mood

Depression is a major cause of mental illness in the world.1 Yet only half of those with the condition receive treatment. In order to improve outcomes, healthcare professionals must be able to identify and treat patients who have the highest probability of responding to certain treatments.

The ability to tailor depression treatments is one method to achieve this. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will benefit most from certain treatments. They are using sensors on mobile phones, a voice assistant with artificial intelligence as well as other digital tools. Two grants were awarded that total more than $10 million, they will make use of these tools to identify biological and behavioral predictors of response to antidepressant medications and psychotherapy.

The majority of research to the present has been focused on clinical and sociodemographic characteristics. These include factors that affect the demographics such as age, gender and education, clinical characteristics such as the severity of symptoms and comorbidities and biological indicators such as neuroimaging and genetic variation.

While many of these factors can be predicted from information available in non medical treatment for depression records, only a few studies have employed longitudinal data to explore predictors of mood in individuals. Few also take into account the fact that mood varies significantly between individuals. Therefore, it is essential to develop methods that permit the identification of different mood predictors for each person and treatments effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team is able to develop algorithms to identify patterns of behaviour and emotions that are unique to each person.

In addition to these methods, the team also developed a machine-learning algorithm to model the dynamic factors that determine a person's depressed mood. The algorithm combines the individual differences to produce an individual "digital genotype" for each participant.

This digital phenotype has been associated with CAT DI scores, a psychometrically validated symptom severity scale. The correlation was low however (Pearson r = 0,08; BH adjusted P-value 3.55 10 03) and varied greatly between individuals.

Predictors of symptoms

Depression is the leading cause of disability in the world1, but it is often not properly diagnosed and treated. In addition an absence of effective treatments and stigma associated with depressive disorders prevent many individuals from seeking help.

To allow for individualized treatment, identifying predictors of symptoms is important. The current prediction methods rely heavily on clinical interviews, which aren't reliable and only identify a handful of characteristics that are associated with depression.

Machine learning can enhance the accuracy of diagnosis and treatment for depression treatment in pregnancy (mouse click the up coming website) by combining continuous digital behavioral phenotypes gathered from smartphones with a valid mental health tracker online (the Computerized Adaptive Testing psychotic depression treatment Inventory CAT-DI). These digital phenotypes allow continuous, high-resolution measurements as well as capture a wide variety of unique behaviors and activity patterns that are difficult to document with interviews.

The study involved University of California Los Angeles (UCLA) students who were suffering from mild to severe depression symptoms. who were enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29 developed under the UCLA Depression Grand Challenge. Participants were directed to online support or in-person clinical treatment depending on their depression severity. Patients who scored high on the CAT-DI of 35 65 were assigned online support with the help of a coach. Those with a score 75 patients were referred for in-person psychotherapy.

Participants were asked a set of questions at the beginning of the study about their psychosocial and demographic characteristics as well as their socioeconomic status. These included age, sex, education, work, and financial situation; whether they were divorced, married or single; the frequency of suicidal ideation, intent or attempts; and the frequency at that they consumed alcohol. Participants also scored their level of depression treatment in islam symptom severity on a scale of 0-100 using the CAT-DI. The CAT-DI tests were conducted every other week for the participants that received online support, and every week for those who received in-person care.

Predictors of Treatment Reaction

Research is focusing on personalized treatment for depression. Many studies are aimed at finding predictors that can aid clinicians in identifying the most effective drugs to treat each patient. In particular, pharmacogenetics identifies genetic variations that affect how the body's metabolism reacts to antidepressants. This lets doctors select the medication that will likely work best for each patient, reducing the amount of time and effort required for trial-and error treatments and avoid any negative side consequences.

Another promising method is to construct prediction models using multiple data sources, including the clinical information with neural imaging data. These models can then be used to identify the most effective combination of variables predictive of a particular outcome, such as whether or not a drug is likely to improve the mood and symptoms. These models can be used to predict the response of a patient to a treatment, which will help doctors maximize the effectiveness.

A new generation uses machine learning techniques like supervised and classification algorithms such as regularized logistic regression, and tree-based methods to integrate the effects of multiple variables and increase the accuracy of predictions. These models have been demonstrated to be useful in predicting the outcome of treatment like the response to antidepressants. These approaches are becoming more popular in psychiatry, and are likely to be the norm in future treatment.

In addition to ML-based prediction models, research into the underlying mechanisms of depression is continuing. Recent research suggests that the disorder is associated with dysfunctions in specific neural circuits. This suggests that an individualized depression treatment will be based on targeted treatments that target these neural circuits to restore normal functioning.

Internet-based interventions are an effective method to accomplish this. They can offer a more tailored and individualized experience for patients. One study found that an internet-based program improved symptoms and led to a better quality life for MDD patients. Additionally, a randomized controlled trial of a personalized approach to treating depression treatment resistant showed an improvement in symptoms and fewer adverse effects in a significant percentage of participants.

Predictors of Side Effects

In the treatment of situational depression treatment, one of the most difficult aspects is predicting and determining the antidepressant that will cause very little or no adverse negative effects. Many patients are prescribed a variety medications before settling on a treatment that is safe and effective. Pharmacogenetics offers a fascinating new avenue for a more efficient and specific method of selecting antidepressant therapies.

There are several variables that can be used to determine the antidepressant to be prescribed, including gene variations, patient phenotypes such as gender or ethnicity, and co-morbidities. To determine the most reliable and valid predictors for a particular treatment, random controlled trials with larger sample sizes will be required. This is due to the fact that it can be more difficult to determine interactions or moderators in trials that only include one episode per person instead of multiple episodes over time.

Furthermore, the estimation of a patient's response to a particular medication will also likely require information on the symptom profile and comorbidities, as well as the patient's prior subjective experiences with the effectiveness and tolerability of the medication. At present, only a handful of easily identifiable sociodemographic variables and clinical variables appear to be reliably related to response to MDD. These include age, gender and race/ethnicity, SES, BMI and the presence of alexithymia.

The application of pharmacogenetics to treatment for depression is in its beginning stages, and many challenges remain. First, a clear understanding of the underlying genetic mechanisms is needed and an understanding of what constitutes a reliable predictor for treatment response. Additionally, ethical issues, such as privacy and the appropriate use of personal genetic information must be carefully considered. In the long term the use of pharmacogenetics could provide an opportunity to reduce the stigma associated with mental health care and improve the outcomes of those suffering with depression. Like any other psychiatric treatment it is essential to take your time and carefully implement the plan. At present, it's recommended to provide patients with a variety of medications for depression that work and encourage patients to openly talk with their physicians.